USFDA issues warning to Shilpa Medicare for CGMP violations at Telangana plant

"This warning letter summarises significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals ...Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," the USFDA said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2HNPADg
via IFTTT